PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM

Abstract Among a cohort of men who have sex with men in a pre-exposure prophylaxis (PrEP) adherence trial, syphilis requiring treatment was associated with white coat dosing (increased PrEP adherence immediately preceding study visits) when compared with participants with optimal drug concentrations. The findings highlight the need for identifying and reducing barriers to PrEP adherence.

[1]  J. Bauermeister,et al.  Barriers and Facilitators of PrEP Adherence for Young Men and Transgender Women of Color , 2019, AIDS and Behavior.

[2]  Kimberly A. Koester,et al.  Adherence to PrEP Among Young Men Who Have Sex With Men Participating in a Sexual Health Services Demonstration Project in Alameda County, California. , 2019, Journal of acquired immune deficiency syndromes.

[3]  L. Myer,et al.  A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women. , 2019, Journal of acquired immune deficiency syndromes.

[4]  J. Baeten,et al.  Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test , 2019, Journal of acquired immune deficiency syndromes.

[5]  R. Bolan,et al.  Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles , 2019, AIDS care.

[6]  Elizabeth A Torrone,et al.  Reported Primary and Secondary Syphilis Cases in the United States: Implications for HIV Infection , 2018, Sexually transmitted diseases.

[7]  P. Anderson.  What Can Urine Tell Us About Medication Adherence? , 2018, EClinicalMedicine.

[8]  E. Daar,et al.  Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men , 2018, The Journal of infectious diseases.

[9]  J. Haberer,et al.  Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring , 2018, Current HIV/AIDS Reports.

[10]  C. Tseng,et al.  Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California , 2017, Journal of acquired immune deficiency syndromes.

[11]  A. van der Straten,et al.  Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. , 2017 .

[12]  N. Brewer,et al.  Mailed Human Papillomavirus Self-Collection With Papanicolaou Test Referral for Infrequently Screened Women in the United States , 2017, Sexually transmitted diseases.

[13]  K. Driscoll,et al.  White Coat Adherence Occurs in Adolescents With Type 1 Diabetes Receiving Intervention to Improve Insulin Pump Adherence Behaviors , 2017, Journal of diabetes science and technology.

[14]  Peter L. Anderson,et al.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing , 2016, Antimicrobial Agents and Chemotherapy.

[15]  J. Mellors,et al.  Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? , 2016, Current opinion in HIV and AIDS.

[16]  A. van der Straten,et al.  Disclosure of pharmacokinetic drug results to understand nonadherence , 2015, AIDS.

[17]  W. Nilsen,et al.  Self-report measures of medication adherence behavior: recommendations on optimal use , 2015, Translational behavioral medicine.

[18]  Megha L Mehrotra,et al.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. , 2014, The Lancet. Infectious diseases.

[19]  L. van Damme,et al.  FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis , 2014, Journal of acquired immune deficiency syndromes.

[20]  E. Gardner,et al.  Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. , 2012, AIDS research and human retroviruses.

[21]  J. Rausch,et al.  White coat adherence over the first year of therapy in pediatric epilepsy. , 2012, The Journal of pediatrics.

[22]  Peter L. Anderson,et al.  Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men , 2012, Science Translational Medicine.

[23]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[24]  B. Vrijens,et al.  “White Coat Compliance” Limits the Reliability of Therapeutic Drug Monitoring in HIV-1—Infected Patients , 2008, HIV clinical trials.

[25]  A R Feinstein,et al.  On white-coat effects and the electronic monitoring of compliance. , 1990, Archives of internal medicine.